EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Castration-resistant prostate cancer is the lethal condition suffered by prostate cancer patients that become refractory to androgen deprivation therapy. EPI-001 is a recently identified compound active against this condition that modulates the activity of the androgen receptor, a nuclear receptor that is essential for disease progression. The mechanism by which this compound exerts its inhibitory activity is however not yet fully understood. Here we show, by using high resolution solution nuclear magnetic resonance spectroscopy, that EPI-001 selectively interacts with a partially folded region of the transactivation domain of the androgen receptor, known as transactivation unit 5, that is key for the ability of prostate cells to proliferate in the absence of androgens, a distinctive feature of castration-resistant prostate cancer. Our results can contribute to the development of more potent and less toxic novel androgen receptor antagonists for treating this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intrinsically disordered protein
Dunker, A. K., Lawson, J. D., Brown, C. J., Williams, R. M., Romero, P., Oh, J. S., Oldfield, C. J., Campen, A. M., Ratliff, C. M., Hipps, K. W., et al. (2001) · Journal of Molecular Graphics and Modelling · doi:10.1016/s1093-3263(00)00138-8 · Cited by 2,272
Elucidating the folding problem of helical peptides using empirical parameters
Muñoz, V., & Serrano, L. (1994) · Nature Structural & Molecular Biology · doi:10.1038/nsb0694-399 · Cited by 721
Structural basis of androgen receptor binding to selective androgen response elements
Shaffer, P. L., Jivan, A., Dollins, D. E., Claessens, F., & Gewirth, D. T. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401123101 · Cited by 400
Conformational Analysis of the Androgen Receptor Amino-terminal Domain Involved in Transactivation
Reid, J., Kelly, S. M., Watt, K., Price, N. C., & McEwan, I. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201003200 · Cited by 143
Self-citationInterplay between two hormone-independent activation domains in the androgen receptor.
Callewaert, L., Van Tilborgh, N., & Claessens, F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2389 · Cited by 111
Induced α-Helix Structure in AF1 of the Androgen Receptor upon Binding Transcription Factor TFIIF
Kumar, R., Betney, R., Li, J., Thompson, E. B., & McEwan, I. J. (2004) · Biochemistry · doi:10.1021/bi035934p · Cited by 107
Self-citationAndrogen receptor decoy molecules block the growth of prostate cancer.
Quayle, S. N., Mawji, N. R., Wang, J., & Sadar, M. D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606718104 · Cited by 84
Dehm, S. M., Regan, K. M., Schmidt, L. J., & Tindall, D. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1267 · Cited by 84
Cited by
Modulating biomolecular condensates: a novel approach to drug discovery
Mitrea, D. M., Mittasch, M., Gomes, B. F., Klein, I. A., & Murcko, M. A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00505-4 · Cited by 401
Intrinsically disordered proteins and biomolecular condensates as drug targets
Biesaga, M., Frigolé-Vivas, M., & Salvatella, X. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.02.009 · Cited by 115
Self-citationRational optimization of a transcription factor activation domain inhibitor
Basu, S., Martínez-Cristóbal, P., Frigolé-Vivas, M., Pesarrodona, M., Lewis, M., Szulc, E., Bañuelos, C. A., Sánchez-Zarzalejo, C., Bielskutė, S., Zhu, J., et al. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01159-5 · Cited by 83
“Tau-5* (330–448 aa) was expressed and purified as previously described 23 , and an equivalent protocol was used to express and purify fragment AR AD (441–558 aa).”
InfluentialSelf-citationEftekharzadeh, B., Banduseela, V. C., Chiesa, G., Martínez-Cristóbal, P., Rauch, J. N., Nath, S. R., Schwarz, D. M. C., Shao, H., Marin-Argany, M., Di Sanza, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11594-y · Cited by 76
Self-citation
Metadata
- Authors
- De Mol, E., Fenwick, R. B., Phang, C. T. W., Buzón, V., Szulc, E., de la Fuente, A., Escobedo, A., García, J., Bertoncini, C. W., Estébanez-Perpiñá, E., McEwan, I. J., Riera, A., & Salvatella, X.
- Venue
- ACS Chemical Biology
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-07-14
- Volume
- 11
- Issue
- 9
- Pages
- 2499-2505
- ISSN
- 1554-8929 (ISSN-L)
- 1554-8937
- OpenAlex
- W2464082044
- Cited by
- 147
- References
- 8
- FWCI
- 9.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor. https://app.cochat.ai/papers/10.1021/acschembio.6b00182
- The paper
- De Mol, E., Fenwick, R. B., Phang, C. T. W., Buzón, V., Szulc, E., de la Fuente, A., Escobedo, A., García, J., Bertoncini, C. W., Estébanez-Perpiñá, E., McEwan, I. J., Riera, A., & Salvatella, X. (2016). EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor. ACS Chemical Biology. https://doi.org/10.1021/acschembio.6b00182
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.